Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 01 - 06 tags : Pharm-country save search
Rafael Pharmaceuticals Announces Successful Completion of Dose Escalation with No Dose-Limiting Toxicity (DLT) in First Cohort of APOLLO 613 Phase
Published: 2022-01-06 (Crawled : 21:00) - biospace.com/
RFL 4 | $1.71 0.0% 4.2K
|
Finance
|
| O: 5.98%
H: 0.4%
C: -2.62%
als ces 613
Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022
Published: 2022-01-06 (Crawled : 21:00) - biospace.com/
CYCC | $2.3 28.49% 22.17% 430K
|
Health Technology
|
| O: -1.33%
H: 1.84%
C: -2.33%
als ces cel
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
Published: 2022-01-06 (Crawled : 19:00) - biospace.com/
AVXL | $3.4 -7.61% -8.24% 2M
|
Health Technology
|
| O: 1.17%
H: 2.89%
C: 0.77%
ces life science anavex
Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors
Published: 2022-01-06 (Crawled : 19:00) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 0.21%
H: 1.74%
C: -2.09%
ces
Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
IMCR | $58.52 2.11% 2.07% 390K
|
Manufacturing
|
| O: 0.82%
H: 2.94%
C: -4.97%
health thc conference j.p. morgan healthcare conference
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
RLYB | News | $1.59 -8.62% -9.43% 280K
|
|
| O: 0.83%
H: 6.82%
C: 5.88%
milestone
IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 4.66%
H: 2.34%
C: 2.34%
genetic trial cel phase 1 therapy t-cell glioblastoma
BD Publishes 2021 Cybersecurity Annual Report
Published: 2022-01-06 (Crawled : 12:00) - biospace.com/
BDX | $233.83 -0.23% 3.49% 780K
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
cybersecurity security
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.